[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342102-105":59,"doc-detail-342102-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","leveraging-single-dose-human-papillomavirus-vaccination-dose-efficiency-to-attain-cervical-cancer-elimination-in-resource-constrained-settings","Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings","","Resource constraints in low- and middle-income countries limit access to cervical cancer prevention. This monograph uses simulation models calibrated to country-specific data and single-dose protection scenarios based on International Agency for Research on Cancer India vaccine trial evidence to estimate impact in India, Rwanda, and Brazil. It compares 1-dose versus the existing 2-dose program while testing resource reallocation approaches. Results suggest dose-efficient strategies paired with single-dose vaccination can prevent more cervical cancers than 2-dose vaccination, supporting cervical cancer elimination progress when resources are tailored to country needs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/leveraging-single-dose-human-papillomavirus-vaccination-dose-efficiency-to-attain-cervical-cancer-elimination-in-resource-constrained-settings/342102/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/leveraging-single-dose-human-papillomavirus-vaccination-dose-efficiency-to-attain-cervical-cancer-elimination-in-resource-constrained-settings/342102.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is single-dose HPV vaccination considered in resource-constrained settings?","Question",{"text":112,"@type":113},"Resource limitations restrict access to cervical cancer preventive measures. Single-dose immunization could improve vaccination access while supporting progress toward cervical cancer elimination.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the study scenarios and country impacts estimated?",{"text":117,"@type":113},"The study applied simulation models using country-specific data and single-dose protection scenarios derived from International Agency for Research on Cancer India vaccine trial information.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the study conclude about switching from 2-dose to 1-dose vaccination?",{"text":121,"@type":113},"Assuming long-term single-dose protection, switching to 1-dose and reallocating resources (especially to female catch-up and improved routine coverage) can prevent more cervical cancer cases than the 2-dose program in several settings, with Rwanda showing less favorable elimination outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342102,1790269093,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Journal of the National Cancer Institute Monographs, 2024, 2024(67), 400–409  \n[https://doi.org/10.1093/jncimonographs/lgae035](https://doi.org/10.1093/jncimonographs/lgae035)  \nMonograph  \nLeveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings  \nIrene Man , PhD,1 Damien Georges , MSc,1 Partha Basu , MD,1 Iacopo Baussano , MD1,􀀃 1Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France  \n􀀃 Correspondence to: Iacopo Baussano, MD, Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, 25 Avenue Tony Garnier, 69366 Lyon Cedex 07, France ([e-mail: baussanoi@iarc.who.int](e-mail: baussanoi@iarc.who.int)) .  \nAbstract  \nBackground: In low-and middle-income countries, resource constraints remain a critical factor limiting access to cervical cancer preventive measures. The option of single-dose immunization could help improve access to human papillomavirus vaccination and attain cervical cancer elimination.  \nMethods: With simulation models adapted to country-specific data and scenarios for single-dose protection derived from International Agency for Research on Cancer India vaccine trial data, we estimated the expected impact of single-dose vaccination in India, Rwanda, and Brazil, three countries with varying profiles of cervical cancer risk and vaccination timelines. In combination with single-dose vaccination, we explored different resource reallocation strategies based on dose efficiency, elimination attainment, and cervical cancer cases prevented, with the existing 2-dose program as a comparator.  \nResults: Assuming lifelong single-dose protection, switching from 2-dose to 1-dose vaccination and reallocating resources to female catch-up could prevent 467-1336, 94-194, and 15-207 additional cervical cancer cases (per 100 000 women born) in cohorts aged 11-30 years in India, Rwanda, and Brazil, respectively. Resource reallocation to improve the current routine coverage could help eliminate cervical cancer in India and across all Brazilian states but not in Rwanda. For each country, we found a dose-efficient reallocation strategy (or a combination of strategies) together with 1-dose vaccination that could prevent more cervical cancers vs 2-dose vaccination, even in the worst-case scenario of single-dose protection.  \nConclusion: Adopting single-dose vaccination with resource reallocation is a resource-efficient approach to enhance progress toward cervical cancer elimination. The overall impact of vaccination can be maximized by fine-tuning resource reallocation to a country’s needs.  \nIn resource-constrained settings, the burden of cervical cancer is disproportionately high and access to preventive measures limited (1) . Although most high-income countries have already introduced human papillomavirus (HPV) vaccination, approximately 40% of low- and middle-income countries (LMICs) have not (as of 2023) (2), and approximately 73% of women living in LMICs, aged 30-49 years, have never undergone cervical cancer screening (as of 2022) (3) . Unless the coverage of these preventive measures substantially improves, many LMICs will likely not reach the cervical cancer elimination threshold of 4 cases per 100 000 women-year, proposed by the World Health Organization (WHO) (4 , 5) .  \nIn this context, the 2022 update of the WHO recommendations to include the single-dose option of HPV could be a game changer (6) . It has now been convincingly shown that a 1 dose of HPV vaccine elicits high-efficacy noninferior to 2 doses, for at least 3 years postvaccination, in the KENya Single-dose HPV-vaccine Efficacy (KEN SHE) Study vaccine trial, which includes randomized singledose arms (of Cervarix and Gardasil-9) (7) . These data corroborate studies with longer follow-up but no designed randomized single-  \ndose arms, notably the Costa Rica vaccine trial’s 16-years data (on ","cbCail5TLEJEseqz","https://ap.wps.com/l/cbCail5TLEJEseqz","pdf",1054252,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion","[{\"question\":\"Why is single-dose HPV vaccination considered in resource-constrained settings?\",\"answer\":\"Resource limitations restrict access to cervical cancer preventive measures. Single-dose immunization could improve vaccination access while supporting progress toward cervical cancer elimination.\"},{\"question\":\"How were the study scenarios and country impacts estimated?\",\"answer\":\"The study applied simulation models using country-specific data and single-dose protection scenarios derived from International Agency for Research on Cancer India vaccine trial information.\"},{\"question\":\"What does the study conclude about switching from 2-dose to 1-dose vaccination?\",\"answer\":\"Assuming long-term single-dose protection, switching to 1-dose and reallocating resources (especially to female catch-up and improved routine coverage) can prevent more cervical cancer cases than the 2-dose program in several settings, with Rwanda showing less favorable elimination outcomes.\"}]","Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings | PDF",1790045209,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e908a749f21cac9e7be89268afbe3890.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ec6082bf87e47a48b9655bdfab0b502.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a56610e4569ae90ffed60115f936d35.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa4ebd9e02951723fdafe4d10c7126e2.webp",980,1287]